[go: up one dir, main page]

DK3154543T3 - PPAR-Forbindelser til anvendelse ved behandlingen af fibrotiske lidelser - Google Patents

PPAR-Forbindelser til anvendelse ved behandlingen af fibrotiske lidelser Download PDF

Info

Publication number
DK3154543T3
DK3154543T3 DK15728018T DK15728018T DK3154543T3 DK 3154543 T3 DK3154543 T3 DK 3154543T3 DK 15728018 T DK15728018 T DK 15728018T DK 15728018 T DK15728018 T DK 15728018T DK 3154543 T3 DK3154543 T3 DK 3154543T3
Authority
DK
Denmark
Prior art keywords
treatment
fibrotic disorders
ppar compounds
ppar
compounds
Prior art date
Application number
DK15728018T
Other languages
English (en)
Inventor
Irena Konstantinova
Jean-Michel Luccarini
Jean-Louis Junien
Pierre Broqua
Original Assignee
Inventiva
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inventiva filed Critical Inventiva
Application granted granted Critical
Publication of DK3154543T3 publication Critical patent/DK3154543T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/428Thiazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Otolaryngology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
DK15728018T 2014-06-13 2015-06-12 PPAR-Forbindelser til anvendelse ved behandlingen af fibrotiske lidelser DK3154543T3 (da)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP14305896 2014-06-13
EP14305895 2014-06-13
EP14305894 2014-06-13
EP14305897 2014-06-13
EP14307187 2014-12-24
PCT/EP2015/063196 WO2015189401A1 (en) 2014-06-13 2015-06-12 Ppar compounds for use in the treatment of fibrotic diseases.

Publications (1)

Publication Number Publication Date
DK3154543T3 true DK3154543T3 (da) 2019-12-02

Family

ID=53373480

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15728018T DK3154543T3 (da) 2014-06-13 2015-06-12 PPAR-Forbindelser til anvendelse ved behandlingen af fibrotiske lidelser

Country Status (24)

Country Link
US (2) US10052311B2 (da)
EP (1) EP3154543B1 (da)
JP (1) JP6557684B2 (da)
KR (1) KR102347721B1 (da)
CN (1) CN106573058B (da)
AU (1) AU2015273454B2 (da)
BR (1) BR112016029129A2 (da)
CA (1) CA2951337C (da)
CY (1) CY1122264T1 (da)
DK (1) DK3154543T3 (da)
EA (1) EA036342B1 (da)
ES (1) ES2755183T3 (da)
HR (1) HRP20191941T1 (da)
HU (1) HUE046293T2 (da)
IL (1) IL249458B (da)
MX (1) MX373268B (da)
PL (1) PL3154543T3 (da)
PT (1) PT3154543T (da)
RS (1) RS59426B1 (da)
SI (1) SI3154543T1 (da)
TN (1) TN2016000535A1 (da)
UA (1) UA120851C2 (da)
WO (1) WO2015189401A1 (da)
ZA (1) ZA201608281B (da)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA202092888A1 (ru) * 2018-07-13 2021-04-19 Кинарус Аг КОМБИНАЦИИ АГОНИСТОВ PPAR И ИНГИБИТОРОВ КИНАЗЫ p38 ДЛЯ ПРЕДОТВРАЩЕНИЯ ИЛИ ЛЕЧЕНИЯ ФИБРОЗИРУЮЩИХ ЗАБОЛЕВАНИЙ
FR3084254B1 (fr) * 2018-07-27 2020-10-23 Inventiva Derives deuteres du lanifibranor
CN110934866B (zh) * 2018-09-25 2023-12-01 深圳微芯生物科技股份有限公司 西格列羧及其相关化合物的应用
US11504380B2 (en) 2019-11-08 2022-11-22 Inventiva Method of treatment of cirrhosis
WO2021161218A1 (en) * 2020-02-11 2021-08-19 Inorbit Therapeutics Ab Sulfinic acid and sulfonic acid compounds for use in modulating peroxisome proliferator-activated receptors
EP4000616A1 (en) 2020-11-17 2022-05-25 Inventiva Combination therapy for the treatment of a liver disease
WO2022122014A1 (zh) 2020-12-11 2022-06-16 苏州科睿思制药有限公司 Lanifibranor的晶型及其制备方法和用途
CN114058694A (zh) * 2021-11-29 2022-02-18 上海市普陀区中心医院 Trpv1在筛选或制备预防、缓解和/或治疗肝脏疾病的药物中的应用
JP2025511354A (ja) 2022-04-06 2025-04-15 シャペロン インク. タウロデオキシコール酸又はその薬学的に許容される塩を有効成分として含有する肺線維症の予防又は治療用組成物
WO2023220332A1 (en) * 2022-05-13 2023-11-16 Children's Hospital Medical Center Methods and compositions for treatment of idiopathic pulmonary fibrosis
WO2025217571A1 (en) * 2024-04-12 2025-10-16 Pliant Therapeutics, Inc. Fixed dose combinations of integrin inhibitor with ppar agonists

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004103296A2 (en) 2003-05-16 2004-12-02 Intermune, Inc. Methods of treating idiopathic pulmonary fibrosis
FR2890071B1 (fr) * 2005-08-30 2007-11-09 Fournier Sa Sa Lab Nouveaux composes de l'indole
NZ567162A (en) 2005-09-07 2011-06-30 Plexxikon Inc 1, 3-disubstituted indole derivatives for use as PPAR modulators
JP2007112720A (ja) * 2005-10-18 2007-05-10 Kissei Pharmaceut Co Ltd メタボリックシンドローム予防又は治療薬
JP5248747B2 (ja) * 2006-01-19 2013-07-31 キッセイ薬品工業株式会社 アディポネクチン受容体発現賦活薬
JP5627574B2 (ja) 2008-06-03 2014-11-19 インターミューン, インコーポレイテッド 炎症性および線維性疾患を治療するための化合物および方法
EP2229951A1 (en) 2009-03-08 2010-09-22 Stichting Katholieke Universiteit Methods for the treatment or prevention of systemic sclerosis
KR101865677B1 (ko) 2009-11-26 2018-07-16 장피트 간 질환 치료를 위한 1,3-디페닐프로프-2-엔-1-온 유도체의 용도
MX2012013574A (es) 2010-05-26 2013-01-24 Bayer Ip Gmbh El uso de estimuladores de la sgc, activadores de la sgc, solos y en combinacion con inhibidores de la pde5 para el tratamiento de esclerosis sistemica (ecs).
WO2012159107A1 (en) 2011-05-19 2012-11-22 Rhode Island Hospital Inhibition of renal fibrosis
KR20190135545A (ko) 2011-10-28 2019-12-06 루메나 파마수티컬즈, 인코포레이티드 고담혈증 및 담즙 정체성 간 질환 치료용 담즙산 재순환 억제제
WO2013071077A1 (en) * 2011-11-09 2013-05-16 Cornell University The use of pan-ppar agonists for prevention and treatment of huntington's disease and tauopathies
JP6293137B2 (ja) 2012-07-18 2018-03-14 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 慢性腎臓病(ckd)を予防および処置するための方法

Also Published As

Publication number Publication date
KR102347721B1 (ko) 2022-01-05
EP3154543A1 (en) 2017-04-19
SI3154543T1 (sl) 2019-12-31
HUE046293T2 (hu) 2020-02-28
CY1122264T1 (el) 2020-11-25
EA036342B1 (ru) 2020-10-29
IL249458B (en) 2020-08-31
MX373268B (es) 2020-04-16
US20170189383A1 (en) 2017-07-06
PL3154543T3 (pl) 2020-02-28
UA120851C2 (uk) 2020-02-25
AU2015273454A1 (en) 2017-01-05
BR112016029129A2 (pt) 2018-01-30
WO2015189401A1 (en) 2015-12-17
PT3154543T (pt) 2019-11-04
JP6557684B2 (ja) 2019-08-07
CA2951337C (en) 2022-08-23
MX2016016534A (es) 2017-04-06
JP2017524663A (ja) 2017-08-31
TN2016000535A1 (en) 2018-04-04
US10383858B2 (en) 2019-08-20
ZA201608281B (en) 2018-05-30
US10052311B2 (en) 2018-08-21
EP3154543B1 (en) 2019-08-28
IL249458A0 (en) 2017-02-28
ES2755183T3 (es) 2020-04-21
US20180333396A1 (en) 2018-11-22
CN106573058A (zh) 2017-04-19
CN106573058B (zh) 2020-05-05
KR20170042504A (ko) 2017-04-19
EA201692433A1 (ru) 2017-05-31
AU2015273454B2 (en) 2019-09-05
RS59426B1 (sr) 2019-11-29
HRP20191941T1 (hr) 2020-01-10
CA2951337A1 (en) 2015-12-17

Similar Documents

Publication Publication Date Title
DK3119397T3 (da) Heterocykliske forbindelser til anvendelse i behandling af PI3K-gamma-medierede lidelser
DK3185957T3 (da) Patisiran til anvendelse ved behandlingen af transthyretin-medieret amyloidosis
IL247452A0 (en) Compounds for treatment of complement mediated disorders
DK3307262T3 (da) Forbindelser til anvendelse ved behandling af neuromuskulære lidelser
DK3125875T3 (da) Inhalerbar rapamycinformulering til behandling af aldersrelaterede tilstande
DK3492632T3 (da) Metoder til behandling af lithiumholdige materialer
DK3134530T3 (da) Behandling af hyperbilirubinæmi
DK3154543T3 (da) PPAR-Forbindelser til anvendelse ved behandlingen af fibrotiske lidelser
IL257252A (en) Methods of treating fgf21-associated disorders
DK3240612T3 (da) Fremgangsmåder til behandling af nethindesygdomme
DK3433266T3 (da) Fremgangsmåder til behandling af mitokondrieforstyrrelser
DK3481846T3 (da) 11-substituerede 24-hydroxysteroler til anvendelse til behandling af nmda-relaterede tilstande
DK3456330T3 (da) Cortexolon-17alpha-valerat til anvendelse ved behandling af tumorer
DK3157534T3 (da) Acetylcholinesterasehæmmere til behandling af dermatologiske tilstande
DK3134084T3 (da) Fremgangsmåde til behandling af lungeadenokarcinom
DK3302519T3 (da) Ornithodoros-moubata-komplement-inhibitor til anvendelse i behandlingen af akut graft-versus-host-sygdom
BR112016022976A2 (pt) Métodos para o tratamento de hcv
DK3236960T3 (da) Fluralaner til anvendelse i behandling af demodicose
DK3191513T3 (da) Anvendelse af reslizumab til behandling af moderat til svær eosinofil astma
DK3192524T3 (da) Hgf præparat egnet til behandling af neurologiske lidelser
DK3209295T3 (da) Fremgangsmåder til behandling af øjenlidelser
DK3125874T3 (da) Et terapeutisk middel til anvendelse i behandlingen af infektioner
DK3169405T3 (da) Fremgangsmåder, forbindelser og sammensætninger til behandling af muskel- og skeletsygdomme
DK3855181T3 (da) Forbindelser til behandling af lipofuscinrelaterede sygdomme
DK3096775T3 (da) SOCS-mimetika til behandling af sygdomme